Mar. 21 at 8:21 PM
$IBRX FDA should approve papillary-only indication ASAP 🙏 -- it's the right thing to do. Bear in mind, SOC failure in this population ultimately leads to bladder removal (~50-70%), with the remaining ~30-50% being medically unfit to undergo cystectomy or being fit but refusing surgery, who are then subject to ongoing disease burden, higher morbidity and progression risk. In this context, a therapy (Anktiva) that delays or avoids cystectomy and controls disease with acceptable safety is highly valuable.
